公司认证与行业地位 - 公司获得国际无人系统协会认证，成为可信无人海事系统操作员培训提供商，标志着无人水面艇操作专业化的重要里程碑 [1] - 公司成为全国首个行业主导的无人海事系统框架下，有资格提供AUVSI认证培训的少数组织之一 [2] - 通过此认证，公司加入了推动无人系统行业安全、专业化和创新的可信提供商网络 [6] 培训业务详情 - 培训服务面向政府、国防、商业和学术领域的专业人士，旨在获得无人水面艇操作认证 [3] - 培训将使用公司成熟的WAM-V®平台进行，该平台以适应性、稳定性和多任务 versatility 著称 [3] - 此项培训是创收业务，将在公司位于太平洋和大西洋的地点以及客户现场提供 [3] 战略意义与市场影响 - 认证强化了公司对推进安全、有效和专业无人操作的承诺，并支持其经常性收入努力 [4][6] - 培训计划旨在确保操作员能够以最高的安全和能力标准完成任务目标 [4] - 该认证扩大了符合新兴监管、操作和安全标准的操作员培训渠道，支持无人海事行业的持续增长 [5] 公司业务概览 - 公司为国防和安全、石油和天然气、科学与研究以及海上风电市场提供智能海事解决方案和服务 [8] - 公司产品组合包括Merrows™ AI集成系统、PowerBuoy®平台以及WAM-V®自主水面艇和海洋机器人服务 [8]

MOUNTAIN VIEW, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will be participating at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum, to be held on November 20, 2025. Mr. Bagai will share an update on RenovoRx’s c ...

MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025. The Company is scheduled to present at 8:00 a.m. (GMT) / 4:00 a.m. (ET) the same day via webcast. A live audio we ...

Lakewood, NJ, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (NASDAQ: RELI) (“Reliance” or the “Company”), announced today that it will host a conference call Thursday, November 6, 2025, at 4:30 PM Eastern Time to discuss financial results for the third quarter 2025 and provide a business update. The conference call will be available via telephone by dialing toll-free +1 800-715-9871 for U.S. callers or +1 646-307-1963 for international callers and entering access code Reliance Global Group I ...

公司战略与人事任命 - 公司任命以色列海军前总司令Eli Marum上将和美国前驻巴哈马大使Ned L Siegel加入其顾问委员会[1] - 此次任命旨在将公司定位为下一代技术与盟国国家安全创新之间的桥梁[2] - 新任顾问将帮助公司扩大全球合作伙伴关系和战略计划[9] 新任顾问背景与专长 - Eli Marum上将在以色列海军担任过几乎所有高级指挥职务，包括海军作战部长和总司令，并领导了2006年黎巴嫩战争后以色列海军的全面现代化和战略重建[3][4] - Ned L Siegel大使拥有超过四十年的外交、商业和政策经验，曾担任美国驻巴哈马大使，并在私营部门担任专注于房地产、能源、基础设施和安全技术的国际商业咨询公司总裁[6][7] - 两位新任顾问与公司现有顾问、英国前议员及国家安全政策制定者Ben Everitt共同体现了公司对强有力治理、国际合作和使命驱动创新的持续承诺[10] 公司业务与技术定位 - 公司是一家国防技术和人工智能驱动的传感公司，开发和商业化集成基于人工智能的传感、雷达和自主系统的下一代国防技术，应用于空中、陆地和海上领域[11] - 公司的使命是为全球政府、国防和商业客户增强态势感知、安全性和决策能力[11] - 公司强调其不仅开发技术，更在建立重新定义国防创新如何触及现实世界的联系[9]

Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern TimeCARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its third quarter 2025, for the period ended September 30, 2025, on Tuesday, November 11, 2025, before market ...

— Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7% — Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth — First nine months revenue of $58.7M, +42% year-over-year growth; IFRS gross margin of 75.1% — First nine months IFRS and non-IFRS net income of $1.4M and $3.2M, respectively, versus a net loss of $3.8M and $2.1M, respectively, in the same year ago period — Approximately 667,00 pulse treatments administered since commer ...

VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Leviathan Gold Ltd. (“Leviathan” or the “Company”) (LVX – TSXV, LVXFF – OTC, 0GP – FSE) is pleased to announce that it has received conditional approval of the TSX Venture Exchange (the “TSXV”) with respect to the previously announced proposed acquisition (the “Transaction”) of all of the issued and outstanding securities of Cura Exploration Botswana Corp. (“Cura”), further to its previous announcements on June 19, 2025, July 16, 2025, August 18 ...

MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call ...

合作核心内容 - MACOM与HRL实验室达成协议 获得HRL专有的40nm T3L GaN-on-SiC工艺技术的授权和制造权 [1] - 双方将合作快速将该专有半导体工艺从HRL工厂转移到MACOM的一家美国可信代工厂 [1] - MACOM将获得基于T3L工艺制造产品的独家授权 [1] 技术细节与优势 - T3L工艺采用专有的外延结构和先进的栅极设计 使其在毫米波频率下具有领先的性能和更高的可靠性 [2] - 该工艺非常适用于支持商业和国防应用 [2] - T3L是业界最先进的高频半导体工艺之一 [4] 技术开发背景 - T3L工艺由HRL在美国国防部副部长办公室的STARRY NITE项目和DARPA的DREaM项目下 以及HRL的额外资金支持下成熟起来 [3] - HRL由波音和通用汽车共同拥有 长期被公认为射频和微波GaN-on-SiC工艺技术研发领域的先驱 [2][6] 公司业务与影响 - MACOM为电信 工业与国防以及数据中心行业设计和制造高性能半导体产品 每年为超过6000家客户提供服务 [5] - 此次合作将使MACOM及其客户受益于T3L工艺的成果 预计将增强公司现有产品组合并加速其路线图的执行 [4] - 与MACOM的合作展示了HRL在开发和验证技术概念 并将其转化为生产方面的专业知识 [4]